Ildong Pharmaceutical announced on the 3rd that its type 2 diabetes combination drug 'Qtern 5/10mg' was registered as an item subject to medical care benefit as of May 1st. As a result, Qtern is covered by insurance as a three-drug therapy drug that can be used in combination with metformin when HbA1c is 7% or higher even if the two-drug therapy is administered for more than 2 to 4 months. 'Qtern 5/10mg' is a combination drug that combines ▲DPP-4 inhibitor Saxagliptin 5mg and ▲SGLT2 inhibitor Dapagliflozin 10mg. In 2016 and 2017, it obtained new drug approval in Europe and the United States, respectively, and in Korea, it was launched in 2021 after item approval from the Ministry of Food and Drug Safety in 2017.